Search results for "Etre"

showing 10 items of 350 documents

Manuel Boix. La Nau, el viatge del temps

2014

Vídeo 'Manuel Boix. La Nau, el viatge del temps'

6299 Ciències de les Arts i les Lletres
researchProduct

Aneurysm clipping following endovascular coil embolization: A report of two cases

2009

Abstract BACKGROUND: Treatment of intracranial aneurysms by Guglielmi detachable coil (GDC) embolization is a useful therapeutic alternative to surgery. This procedure is attractive as a minimally invasive approach to treat cerebral aneurysms; however, is not devoid of complications or failure and retreatment, with either a surgical or endovascular technique, may often be required. CASE REPORTS: Two cases are presented in which surgery was required after coil embolization. In one case, surgical treatment was performed one month later because of regrowth and subsequent bleeding of the aneurysm. In the second case, surgical treatment was carried out six months later because of recanalization …

AdolescentSettore MED/27 - Neurochirurgiaaneurysm rest; cerebral aneurysm; guglielmi detachable coils; retreatmentIntracranial AneurysmMiddle AgedEmbolization Therapeuticcerebral aneurysmguglielmi detachable coilsCerebral aneurysm coli embolizzation subharachnoid hemorrhageCerebral aneurysm clippingHumansFemaleaneurysm restretreatment
researchProduct

Layer-by-Layer Adsorption: The Solid/Liquid-Interface as a Template for the Controlled Growth of Well-Defined Nanostructures of Polyelectrolytes, Pro…

1994

This report describes the construction of ultrathin films whose structure can be tailored on the molecular scale. The resulting supramolecular film architectures may include functional biological macromolecules such as proteins or polynucleotides. The average distances of two functional layers can be adjusted on the nanometer scale (from less than lnm to several tens of nanometers), with a precision of approximately 0.1 nm. This control is achieved by varying the number and the thickness of the polyelectrolyte interlayers and requires the capability of steering each adsorption step with high accuracy. A crucial factor is the fabrication and manipulation of the film surface at each adsorptio…

AdsorptionMaterials scienceNanostructureLayer by layerSupramolecular chemistryNanotechnologyNanometreLayer (electronics)PolyelectrolyteMacromolecule
researchProduct

Entropy of balance--some recent results.

2010

Abstract Background Entropy when applied to biological signals is expected to reflect the state of the biological system. However the physiological interpretation of the entropy is not always straightforward. When should high entropy be interpreted as a healthy sign, and when as marker of deteriorating health? We address this question for the particular case of human standing balance and the Center of Pressure data. Methods We have measured and analyzed balance data of 136 participants (young, n = 45; elderly, n = 91) comprising in all 1085 trials, and calculated the Sample Entropy (SampEn) for medio-lateral (M/L) and anterior-posterior (A/P) Center of Pressure (COP) together with the Hurst…

AdultAgingAdolescentHealth InformaticsModels Psychologicallcsh:RC321-571Developmental psychologyYoung AdultPhysical StimulationStatisticsPostural BalancePressureEntropy (information theory)HumansAttentionlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryEyes openPostural BalanceAgedAged 80 and overResearchSignificant differenceRehabilitationMiddle AgedSample entropyStanding balanceDetrended fluctuation analysisExponentVisual PerceptionAccidental FallsPsychologyJournal of neuroengineering and rehabilitation
researchProduct

Goldmann Tonometry After Hyperopic Laser In Situ Keratomileusis

2004

PURPOSE To identify differences in applanation tonometry between retreated and nonretreated eyes (primary LASIK eyes) 6 months after hyperopic laser in situ keratomileusis. METHODS In a prospective study 100 eyes (100 patients) underwent conventional hyperopic laser in situ keratomileusis under a 160-microm flap. Central Goldmann applanation tonometry was determined before and 6 months after surgery in 78 (78%) primary LASIK eyes and before surgery and 6 months after the retreatment date in 22 (22%) retreated eyes. RESULTS Preoperative mean tonometry was 14.96 +/- 1.96 mm Hg and 15.30 +/- 1.95 mm Hg in primary LASIK and retreated eyes, respectively. Six months after surgery it was 12.99 +/-…

AdultApplanation tonometrymedicine.medical_specialtyIntraocular pressureTime Factorsgenetic structuresmedicine.medical_treatmentKeratomileusis Laser In SitueducationKeratomileusisGoldmann applanation tonometryTonometry OcularmedicineHumansPostoperative PeriodProspective StudiesIntraocular Pressurebusiness.industrySignificant differenceLASIKhumanitieseye diseasesSurgeryGoldmann tonometryOphthalmologyHyperopiaTreatment OutcomeRetreatmentsense organsbusinessCornea
researchProduct

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractor…

2018

AbstractPurpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested.Results:The study included 187 patients. The most common treatment-related adverse events were…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyAdministration OralAntineoplastic AgentsDrug resistanceGastroenterologyYoung Adult03 medical and health sciencesHyperphosphatemia0302 clinical medicineRefractoryErdafitinibNeoplasmsQuinoxalinesInternal medicinemedicineHumansNeoplasmDosingAdverse effectProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overbusiness.industryGenetic VariationMiddle AgedPrognosismedicine.diseaseReceptors Fibroblast Growth FactorTreatment Outcome030104 developmental biologyOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisRetreatmentPyrazolesFemalebusinessClinical Cancer Research
researchProduct

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multi…

2015

This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade≤3. At a bortezomib dose lower than that in other combina…

AdultMaleCancer ResearchCombination therapyPyridinesKaplan-Meier EstimatePalbociclibPharmacologyDexamethasoneDrug Administration SchedulePiperazinesBortezomibRecurrenceCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineMultiple myelomaDexamethasoneAgedNeoplasm StagingAged 80 and overbiologybusiness.industryBortezomibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HematologyMiddle AgedCell cyclemedicine.diseaseTreatment OutcomeOncologyDrug Resistance NeoplasmPharmacodynamicsRetreatmentbiology.proteinFemaleDrug MonitoringMultiple Myelomabusinessmedicine.drugLeukemia & Lymphoma
researchProduct

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorecta…

2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5-fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. METHODS: The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25; median age, 63 years; range, 27-79 years) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy, an irinotecan-based second-line regimen, and a third-line treatment with cetuximab plus weekly irinotecan. Bevacizumab was given at a dose of 5 mg/kg. 5-FU/folinic acid was administered according to the de Gramont schedule. RESULTS: The respo…

AdultMaleCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryOxaliplatinIrinotecanBevacizumabRegimenBevacizumabcolorectal cancerOncologyDrug Resistance NeoplasmRetreatmentFemaleFluorouracilbusinessBevacizumab; Colorectal cancer; cancer combination chemotherapyColorectal Neoplasmsmedicine.drug
researchProduct

Intrauterine therapy of goitrous hypothyroidism in a boy with a new compound heterozygous mutation (Y453D and C800R) in the thyroid peroxidase gene. …

2004

We report the results of intrauterine L-thyroxine therapy, and the long-term follow-up in a fetus who presented at 32 weeks' gestation with goitrous hypothyroidism, hyperextension of the neck, and polyhydramnios. Spontaneous delivery was possible and hypothyroidism improved. Molecular analysis revealed a new compound heterozygous mutation (Y453D/C800R) in the TPO gene.

AdultMalePolyhydramniosendocrine systemmedicine.medical_specialtyPolyhydramniosGoiterendocrine system diseasesCompound heterozygosityIodide PeroxidaseInjectionsLoss of heterozygosityHypothyroidismPregnancyInternal medicineCongenital HypothyroidismMedicineHumansThrombopoietinFetusFetal Therapiesbusiness.industryGoiterObstetrics and Gynecologymedicine.diseaseCongenital hypothyroidismFetal DiseasesThyroxineEndocrinologyRetreatmentGestationFemalebusinessFollow-Up StudiesAmerican journal of obstetrics and gynecology
researchProduct